Abstract
Stem cell and gene therapy approaches have held out much hope for the development of new tools to treat disease. Therapeutic approaches based on these methods have only rarely found their way into the clinic. The linking of stem cell therapy with selective gene therapy enhances therapeutic options for the regeneration or replacement of diseased or missing cells. This review focuses on the rationale and preliminary results of combining stem cell and gene therapy. Special emphasis is placed on various molecular techniques currently used to genetically engineer stem cells. Viral and nonviral genes delivering technologies are detailed as are techniques for the modulation of gene expression in the context of stem cell recruitment and differentiation. Finally potential clinical applications for this new therapeutic strategy are discussed.
Keywords: Cell Therapy, progenitor cells, tissue engineering, gene delivery, stem cell recruitment, cell differentiation, angiogenesis, tumor stem cell
Current Gene Therapy
Title: Genetically Engineered Stem Cells for Therapeutic Gene Delivery
Volume: 7 Issue: 4
Author(s): Claudius Conrad, Rashmi Gupta, Hema Mohan, Hanno Niess, Christiane J. Bruns, Reinhard Kopp, Irene von Luettichau, Markus Guba, Christopher Heeschen, Karl-Walter Jauch, Ralf Huss and Peter J.Nelson
Affiliation:
Keywords: Cell Therapy, progenitor cells, tissue engineering, gene delivery, stem cell recruitment, cell differentiation, angiogenesis, tumor stem cell
Abstract: Stem cell and gene therapy approaches have held out much hope for the development of new tools to treat disease. Therapeutic approaches based on these methods have only rarely found their way into the clinic. The linking of stem cell therapy with selective gene therapy enhances therapeutic options for the regeneration or replacement of diseased or missing cells. This review focuses on the rationale and preliminary results of combining stem cell and gene therapy. Special emphasis is placed on various molecular techniques currently used to genetically engineer stem cells. Viral and nonviral genes delivering technologies are detailed as are techniques for the modulation of gene expression in the context of stem cell recruitment and differentiation. Finally potential clinical applications for this new therapeutic strategy are discussed.
Export Options
About this article
Cite this article as:
Claudius Conrad , Rashmi Gupta , Hema Mohan , Hanno Niess , Christiane J. Bruns , Reinhard Kopp , Irene von Luettichau , Markus Guba , Christopher Heeschen , Karl-Walter Jauch , Ralf Huss and Peter J.Nelson , Genetically Engineered Stem Cells for Therapeutic Gene Delivery, Current Gene Therapy 2007; 7 (4) . https://dx.doi.org/10.2174/156652307781369119
DOI https://dx.doi.org/10.2174/156652307781369119 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PHB in Cardiovascular and Other Diseases: Present Knowledge and Implications
Current Drug Targets Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research Anti-Cancer Potential of Some Commonly Used Drugs
Current Pharmaceutical Design CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Hedgehog Signaling and Urological Cancers
Current Drug Targets Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Antimicrobial and Cytotoxicity Activities of 2-(aryl)-3-(benzo[d][1,3] dioxol-5-yl)thiazolidin-4-ones
Letters in Drug Design & Discovery Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry P53 Mdm2 Inhibitors
Current Pharmaceutical Design Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets Dual Inhibitors of β-Amyloid Aggregation and Acetylcholinesterase as Multi-Target Anti-Alzheimer Drug Candidates
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Microglia - A Therapeutic Target in Neurological Diseases and Disorders)
CNS & Neurological Disorders - Drug Targets Nucleic Acid-Based Therapeutics for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets
Current Medicinal Chemistry